Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

Executive Summary

GDUFA II gives certain generics the possibility of an even faster review clock, which burnishes FDA's credentials in the drug pricing debate, but in order to take advantage, applications will need to be of high quality in addition to addressing a public health priority.


Related Content

EpiPen Price Hearing: House Plays Bootleg Tape Of Shkreli Event
Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances
EpiPen Generics: Woodcock Explains Injector Studies
Biosimilar User Fee Agreement Offers FDA Funding Boost, Fee Structure Overhaul
ANDA Approvals, Submissions Decline With New Review Goal Coming
FDA To ANDA Sponsors: Don't Forget Quality When Rushing For 10-Month Review Goal
Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact
GDUFA II: Priority Reviews Considered For Some ANDAs
ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?
Generic Drugs 2014: OGD Creates Internal Review Goals, May Make OND-Inspired Changes


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts